Hematuria - HealthQuill

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

UroGen Pharma Ltd.’s therapy to treat adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer has been approved by the US Food and Drug Administration.

FDA approves UroGen’s muscle-invasive bladder cancer therapy

HQ Team June 13, 2025: UroGen Pharma Ltd.’s therapy to treat adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer has been.

by HealthQuill
June 13, 2025
0 Comments

About Us

Contact Info

Follow Us

FDA approves UroGen’s muscle-invasive bladder cancer therapy